Outlook 2021: Medtechs Must Look To Late 2021 And 2022 For A Return To Normal Times
Medtech is as attractive as it has ever been says Jefferies Healthcare
Executive Summary
Delivering innovation is still the driving force for medtechs intent on growing in the market, regardless of COVID-19, the disruptive effects of which have intensified with the appearance of new variants, says Jefferies Healthcare equity analyst Raj Denhoy.
You may also be interested in...
Pandemic Perspectives: A Lasting Impact On Medtech, But Not Dealmaking
The COVID-19 pandemic has fundamentally changed health care and the life sciences, KPMG analyst Kristin Pothier concludes in a new report on the medtech investment outlook.
Boston Scientific Gives Up On Lotus Edge TAVR
The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.
Here Comes The NICE Revolution – Agility And Speed Will Drive UK HTA Into A New Era
Evolving health care demands, digital innovation and the need to work within tighter budgets have prompted the UK’s NICE to reset its strategy for the coming five years.